Expertise in
4
conditions

Jakub Radocha

Hradec Kralove, KR, CZ 
Expertise in
4
conditions
Hradec Kralove, KR, CZ 
OverviewLocationsClinical Research

Overview

Jakub Radocha practices in Hradec Kralove, Czech Republic. Mr. Radocha is highly rated in 4 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Plummer-Vinson Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Hradec Kralove, KR, Czech Republic
Other Locations
Brno, JM, Czech Republic
Prague, PR, Czech Republic
Hradec, ST, Czech Republic

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3

63 Total Publications

Which myelofibrosis patients benefit from treatment with ruxolitinib? A single-center experience.
Which myelofibrosis patients benefit from treatment with ruxolitinib? A single-center experience.
Journal: Archives of medical science : AMS
Published: June 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Radocha's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile